Namuscla is a medicine used to treat symptoms of myotonia (muscle stiffness) in patients with non-dystrophic myotonic disorders, a group of inherited muscle disorders. Non-dystrophic means no muscle wasting occurs in patients affected by the condition. Patients with non-dystrophic myotonic disorders experience muscle stiffness and pain because their muscles are slow to relax after contraction. Myotonic disorders are rare, and Namuscla was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 November 2014.
Therapeutic Indication
### Therapeutic indication Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
Therapeutic Area (MeSH)
N/AATC Code
C01BB02
ATC Item
mexiletine
Pharmacotherapeutic Group
Cardiac therapy
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Mexiletine hydrochloride | N/A | 美西律 |
EMA Name
Namuscla
Medicine Name
Namuscla
Aliases
N/ANo risk management plan link.
